Innophos (NASDAQ:IPHS) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

IPHS has been the topic of a number of other reports. Zacks Investment Research raised shares of Innophos from a “hold” rating to a “buy” rating and set a $50.00 target price on the stock in a research note on Friday, December 15th. KeyCorp reissued a “hold” rating on shares of Innophos in a research note on Wednesday, November 1st.

Shares of Innophos (IPHS) traded down $0.17 on Friday, reaching $46.43. 126,962 shares of the company were exchanged, compared to its average volume of 146,240. The stock has a market capitalization of $903.42, a P/E ratio of 21.30 and a beta of 0.85. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.86 and a quick ratio of 1.49. Innophos has a 1-year low of $41.66 and a 1-year high of $58.22.

Innophos (NASDAQ:IPHS) last announced its earnings results on Tuesday, October 31st. The specialty chemicals company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.06. The business had revenue of $184.00 million for the quarter, compared to the consensus estimate of $179.33 million. Innophos had a net margin of 6.19% and a return on equity of 13.90%. Innophos’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period last year, the firm posted $0.69 earnings per share. research analysts anticipate that Innophos will post 2.5 EPS for the current year.

Several hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio raised its stake in shares of Innophos by 379.3% during the third quarter. Public Employees Retirement System of Ohio now owns 13,535 shares of the specialty chemicals company’s stock worth $666,000 after acquiring an additional 10,711 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Innophos by 131.1% during the third quarter. GSA Capital Partners LLP now owns 19,492 shares of the specialty chemicals company’s stock worth $959,000 after acquiring an additional 11,059 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new position in shares of Innophos during the third quarter worth approximately $209,000. Highbridge Capital Management LLC purchased a new position in shares of Innophos during the third quarter worth approximately $265,000. Finally, Segall Bryant & Hamill LLC raised its stake in shares of Innophos by 11.0% during the third quarter. Segall Bryant & Hamill LLC now owns 820,518 shares of the specialty chemicals company’s stock worth $40,361,000 after acquiring an additional 81,550 shares in the last quarter. 94.46% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/06/innophos-iphs-rating-lowered-to-hold-at-bidaskclub.html.

About Innophos

Innophos Holdings, Inc is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. The Company’s segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and Granular Triple Super Phosphate (GTSP) & Other.

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.